menu
    • menu

    Company profile for Neuphoria Therapeutics

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    At Neuphoria, our mission is guided by four core principles that shape every aspect of our work, from groundbreaking research to patient-focused innovation. An unparalleled commitment to developing therapies for people with neuropsychiatric disorders. Cutting edge ion channel targeting coupled with translational expertise and data-driven decision-making.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Neuphoria TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    100 Summit Drive, Burlington, MA 01803
    Telephone
    Telephone
    +1 (781) 730 6665
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.neuphoriatx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Neuphoria Rejects Lynx1's Lower Offer, Maintains Premium Price
    Neuphoria Rejects Lynx1's Lower Offer, Maintains Premium Price

    04 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/04/3199742/0/en/Neuphoria-Responds-to-Lynx1-s-Revised-Indication-of-Interest-at-a-Reduced-Price-and-Premium.html

    GLOBENEWSWIRE
    04 Dec 2025
    Share Share
    Lynx1 Sends Open Letter To Fellow Neuphoria Shareholders
    Lynx1 Sends Open Letter To Fellow Neuphoria Shareholders

    02 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lynx1-sends-open-letter-to-fellow-neuphoria-shareholders-302631101.html

    PR NEWSWIRE
    02 Dec 2025
    Share Share
    Neuphoria Exposes Lynx1 False Narratives With Facts
    Neuphoria Exposes Lynx1 False Narratives With Facts

    01 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/01/3196949/0/en/Neuphoria-Provides-Facts-Exposes-False-Narratives-in-Response-to-Lynx1-Fictions.html

    GLOBENEWSWIRE
    01 Dec 2025
    Share Share
    Neuphoria Therapeutics Sends Letter To Stockholders
    Neuphoria Therapeutics Sends Letter To Stockholders

    24 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/24/3193420/0/en/Neuphoria-Therapeutics-Inc-Sends-Letter-to-Stockholders.html

    GLOBENEWSWIRE
    24 Nov 2025
    Share Share
    Neuphoria, Reeling from Ph. 3 Fail, Mulls Buyout from Investor
    Neuphoria, Reeling from Ph. 3 Fail, Mulls Buyout from Investor

    13 Nov 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/neuphoria-reeling-phase-3-trial-fail-mulls-buyout-offer-investor

    FIERCE BIOTECH
    13 Nov 2025
    Share Share
    Neuphoria Initiates Strategic Review To Boost Shareholder Value
    Neuphoria Initiates Strategic Review To Boost Shareholder Value

    11 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/11/3185300/0/en/Neuphoria-Announces-Initiation-of-Strategic-Review-to-Maximize-Stockholder-Value.html

    GLOBENEWSWIRE
    11 Nov 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search